Iskandar I O
J Int Med Res. 1978;6(4):280-5. doi: 10.1177/030006057800600405.
A study is described which aimed at assessing the efficacy of rifampicin in the treatment of cutaneous leishmaniasis. A total of thirteen patients suffering from this condition were admitted to the study and were given rifampicin 600 mg daily. Three patients dropped out due to reasons unconnected with the trial and one patient left when the lesions improved appreciably and continued treatment abroad. The remaining patients continued under treatment until clinical resolution was attained, and this occurred in a period of one to four months. The author was impressed by the marked clinical resolution and the lack of scarring and side-effects, and recommends that further trials be carried out in the endemic areas where more cases can readily be found, treated and ovserved for longer periods of time than in this study.
本文描述了一项旨在评估利福平治疗皮肤利什曼病疗效的研究。共有13名患有该病的患者纳入该研究，并给予每日600毫克利福平治疗。3名患者因与试验无关的原因退出，1名患者在皮损明显改善后离开并在国外继续治疗。其余患者继续接受治疗直至临床症状消退，这一过程在1至4个月内完成。作者对显著的临床症状消退、无瘢痕形成及副作用印象深刻，并建议在流行地区开展进一步试验，因为在这些地区比本研究更容易找到更多病例，进行更长时间的治疗和观察。
